Cases & Deals

  • Home
  • Practices
  • Celgene files Hatch-Waxman suit against Par Pharmaceutical over generic version of ADHD drug Focalin XR®

Share

Celgene files Hatch-Waxman suit against Par Pharmaceutical over generic version of ADHD drug Focalin XR®

May 2011

Client(s) Celgene Corporation

Jones Day represents Celgene Corporation in a patent infringement action against Par Pharmaceutical brought pursuant to the Hatch-Waxman Act relating to Celgene’s patented drug Focalin XR®.

Celgene Corporation et al. v. Par Pharmaceutical, Inc., Civil Action No. 2-11-cv-03094 (D.N.J.) (Judge Arleo)

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.